clinical trial · NCT05117476
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid TumorNSCLCCLN-619PembrolizumabPaclitaxelCarboplatin AUC 6pemetrexedDatopotamab deruxtecan-dlnk (Dato-DXd)
brief summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
started
Oct 29, 2021
primary completion
Mar 1, 2026
completion
Jun 1, 2026
last updated
Nov 24, 2025
official title
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol